17336-14-0

Basic information

• Product Name: 2-carboxy-4-nitrophenyl acetate
• Synonyms: 2-carboxy-4-nitrophenyl acetate
• CAS NO: 17336-14-0
• Molecular Weight: 225.158
• Mol File: 17336-14-0.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: 2-carboxy-4-nitrophenyl acetate(CAS DataBase Reference)
• NIST Chemistry Reference: 2-carboxy-4-nitrophenyl acetate(17336-14-0)
• EPA Substance Registry System: 2-carboxy-4-nitrophenyl acetate(17336-14-0)

Safety Data

• Hazardous Substances Data: 17336-14-0(Hazardous Substances Data)

Upstream product

• 96-97-9 5-nitrosalicylic acid 
• 108-24-7 acetic anhydride 

Downstream Products

• 96-97-9 5-nitrosalicylic acid 
• 1375074-73-9 4-imino-7-nitro-3-phenyl-2-thioxo-1,2,3,4-tetrahydro-5H-chromeno[2,3-d]pyrimidine-5-one 
• 2497-02-1 N-acetyl-L-histidine 
• 1188-37-0 N-acetyl-(S)-glutamic acid 
• 997-55-7 N-Acetyl-L-aspartic acid 
• 97-69-8 (S)-acetamidoalanine 
• 543-24-8 N-acetylglycine 
• 19479-87-9 (O-carboxymethyl)hydroxylamine 
• 546-88-3 acetylhydroxamic acid 
• 64-19-7 acetic acid 
• 53855-63-3 2-acetyloxy-5-nitrobenzoyl chloride 
• 1245209-66-8 5-nitro-2-acetoxybenzoyl azide 
• 115978-96-6 (Z)-1,3,3-trimethyl-2-(2-hydroxy-5-nitrophenacylidene)indoline 
• 115978-95-5 (E)-1,3,3-trimethyl-2-(2-hydroxy-5-nitrophenacylidene)indoline 

Relevant articles and documents

N-BENZYLANILINE DERIVATIVE AND USES THEREOF

Disclosed are an N-benzylaniline derivative and uses thereof. The derivative is a compound represented by formula I or a pharmaceutically acceptable salt thereof. The compound has an action of protecting against cerebral ischemia/reperfusion injury and an

4-Aminoarylguanidine and 4-aminobenzamidine derivatives as potent and selective urokinase-type plasminogen activator inhibitors

The structure-based design of potent and selective urokinase-type plasminogen activator (uPA) inhibitors with 4-aminoarylamidine or 4-aminoarylguanidine S1 binding groups, is described.

Protease inhibitors

This invention relates to methods of preventing or reducing the degradation of elastin and other proteins and thereby preventing or retarding the disease states caused by said degradation by administering compounds, some of which are novel, of the formula: STR1 or their pharmacologically acceptable salts.